Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades Stock

Core Insights - The U.S. FDA has approved Alnylam Pharmaceuticals' supplemental application for Amvuttra, making it the first and only therapeutic approved for treating ATTR-CM and hATTR-PN in adults [1][2] Group 1: Drug Approval and Indication - Amvuttra is indicated for adults with cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM), aimed at reducing cardiovascular mortality, hospitalizations, and urgent heart failure visits [1][2] - ATTR-CM is characterized by the misfolding of transthyretin (TTR) protein, leading to heart stiffness and potential heart failure [2] Group 2: Market Opportunity and Analyst Insights - JPMorgan has upgraded Alnylam to an Overweight rating, raising the price target from $280 to $328, citing a significant multi-billion dollar opportunity for Amvuttra in TTR amyloidosis [3][4] - Analyst Jessica Fye projects Amvuttra sales in cardiomyopathy to reach approximately $81 million in 2025, an increase from the previous estimate of $79 million [3] Group 3: Stock Performance - Following the news, ALNY stock rose by 3.50%, reaching $293.25 [5]